Home > Publications Database > Advanced structural brain aging in preclinical autosomal dominant Alzheimer disease. > print

001     266753
005     20240403131751.0
024 7 _ |a 10.1186/s13024-023-00688-3
|2 doi
024 7 _ |a pmid:38111006
|2 pmid
024 7 _ |a pmc:PMC10729487
|2 pmc
024 7 _ |a altmetric:157598558
|2 altmetric
037 _ _ |a DZNE-2024-00016
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Millar, Peter R
|0 0000-0003-4588-739X
|b 0
245 _ _ |a Advanced structural brain aging in preclinical autosomal dominant Alzheimer disease.
260 _ _ |a London
|c 2023
|b Biomed Central
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1705483963_18423
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a 'Brain-predicted age' estimates biological age from complex, nonlinear features in neuroimaging scans. The brain age gap (BAG) between predicted and chronological age is elevated in sporadic Alzheimer disease (AD), but is underexplored in autosomal dominant AD (ADAD), in which AD progression is highly predictable with minimal confounding age-related co-pathology.We modeled BAG in 257 deeply-phenotyped ADAD mutation-carriers and 179 non-carriers from the Dominantly Inherited Alzheimer Network using minimally-processed structural MRI scans. We then tested whether BAG differed as a function of mutation and cognitive status, or estimated years until symptom onset, and whether it was associated with established markers of amyloid (PiB PET, CSF amyloid-β-42/40), phosphorylated tau (CSF and plasma pTau-181), neurodegeneration (CSF and plasma neurofilament-light-chain [NfL]), and cognition (global neuropsychological composite and CDR-sum of boxes). We compared BAG to other MRI measures, and examined heterogeneity in BAG as a function of ADAD mutation variants, APOE ε4 carrier status, sex, and education.Advanced brain aging was observed in mutation-carriers approximately 7 years before expected symptom onset, in line with other established structural indicators of atrophy. BAG was moderately associated with amyloid PET and strongly associated with pTau-181, NfL, and cognition in mutation-carriers. Mutation variants, sex, and years of education contributed to variability in BAG.We extend prior work using BAG from sporadic AD to ADAD, noting consistent results. BAG associates well with markers of pTau, neurodegeneration, and cognition, but to a lesser extent, amyloid, in ADAD. BAG may capture similar signal to established MRI measures. However, BAG offers unique benefits in simplicity of data processing and interpretation. Thus, results in this unique ADAD cohort with few age-related confounds suggest that brain aging attributable to AD neuropathology can be accurately quantified from minimally-processed MRI.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Alzheimer disease
|2 Other
650 _ 7 |a Brain aging
|2 Other
650 _ 7 |a Machine learning
|2 Other
650 _ 7 |a Structural MRI
|2 Other
650 _ 7 |a Amyloid beta-Peptides
|2 NLM Chemicals
650 _ 7 |a Amyloid
|2 NLM Chemicals
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 7 |a tau Proteins
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Alzheimer Disease
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides: metabolism
|2 MeSH
650 _ 2 |a Brain: metabolism
|2 MeSH
650 _ 2 |a Amyloid
|2 MeSH
650 _ 2 |a Aging
|2 MeSH
650 _ 2 |a Biomarkers
|2 MeSH
650 _ 2 |a Positron-Emission Tomography
|2 MeSH
650 _ 2 |a tau Proteins: genetics
|2 MeSH
650 _ 2 |a tau Proteins: metabolism
|2 MeSH
700 1 _ |a Gordon, Brian A
|b 1
700 1 _ |a Wisch, Julie K
|b 2
700 1 _ |a Schultz, Stephanie A
|b 3
700 1 _ |a Benzinger, Tammie Ls
|b 4
700 1 _ |a Cruchaga, Carlos
|b 5
700 1 _ |a Hassenstab, Jason J
|b 6
700 1 _ |a Ibanez, Laura
|b 7
700 1 _ |a Karch, Celeste
|b 8
700 1 _ |a Llibre-Guerra, Jorge J
|b 9
700 1 _ |a Morris, John C
|b 10
700 1 _ |a Perrin, Richard J
|b 11
700 1 _ |a Supnet-Bell, Charlene
|b 12
700 1 _ |a Xiong, Chengjie
|b 13
700 1 _ |a Allegri, Ricardo F
|b 14
700 1 _ |a Berman, Sarah B
|b 15
700 1 _ |a Chhatwal, Jasmeer P
|b 16
700 1 _ |a Chrem Mendez, Patricio A
|b 17
700 1 _ |a Day, Gregory S
|b 18
700 1 _ |a Hofmann, Anna
|0 P:(DE-2719)2814244
|b 19
700 1 _ |a Ikeuchi, Takeshi
|b 20
700 1 _ |a Jucker, Mathias
|0 P:(DE-2719)2000010
|b 21
700 1 _ |a Lee, Jae-Hong
|0 P:(DE-HGF)0
|b 22
700 1 _ |a Levin, Johannes
|0 P:(DE-2719)2811659
|b 23
700 1 _ |a Lopera, Francisco
|b 24
700 1 _ |a Niimi, Yoshiki
|b 25
700 1 _ |a Sánchez-González, Victor J
|b 26
700 1 _ |a Schofield, Peter R
|b 27
700 1 _ |a Sosa-Ortiz, Ana Luisa
|b 28
700 1 _ |a Vöglein, Jonathan
|0 P:(DE-2719)2811820
|b 29
700 1 _ |a Network, Dominantly Inherited Alzheimer
|b 30
|e Collaboration Author
700 1 _ |a Bateman, Randall J
|b 31
700 1 _ |a Ances, Beau M
|b 32
700 1 _ |a McDade, Eric M
|b 33
773 _ _ |a 10.1186/s13024-023-00688-3
|g Vol. 18, no. 1, p. 98
|0 PERI:(DE-600)2244557-2
|n 1
|p 98
|t Molecular neurodegeneration
|v 18
|y 2023
|x 1750-1326
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/266753/files/DZNE-2024-00016.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/266753/files/DZNE-2024-00016.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:266753
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 19
|6 P:(DE-2719)2814244
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 21
|6 P:(DE-2719)2000010
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 23
|6 P:(DE-2719)2811659
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 29
|6 P:(DE-2719)2811820
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 1
914 1 _ |y 2023
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-04-12T15:09:14Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-04-12T15:09:14Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-04-12T15:09:14Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-25
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-25
920 1 _ |0 I:(DE-2719)1210001
|k AG Jucker
|l Cell Biology of Neurological Diseases
|x 0
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1210001
980 _ _ |a I:(DE-2719)1111015
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21